Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2025)

ARS Pharmaceuticals' Other Accumulated Expenses history spans 2 years, with the latest figure at $588000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 1300.0% year-over-year to $588000.0; the TTM value through Dec 2025 reached $588000.0, up 1300.0%, while the annual FY2025 figure was $588000.0, 1300.0% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $588000.0 at ARS Pharmaceuticals, down from $3.1 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.1 million in Q3 2025 and bottomed at $42000.0 in Q4 2024.